Drugs in therapy. LSD, MDMA, marijuana, psilocybin, designer drugs and its potential in modern medicine.
Farmacja Polska September 28, 2020 Agata Tadeja 1 citation
Research on psychedelic drugs in medicine was largely halted after the 1971 Convention on Psychotropic Substances, but earlier studies, though methodologically weak, suggested potential benefits. Current studies are exploring the use of substances such as psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), and cannabis in treating psychiatric disorders. Psilocybin therapy, combined with psychotherapy, shows promise for anxiety, depression, and substance abuse. LSD may help terminal cancer patients and drug addicts. MDMA could benefit people with post-traumatic stress disorder or social anxiety in adult autism when standard therapies fail. Cannabis has proven effects for PTSD, epilepsy, neurological pain, and skin conditions. Designer drugs that mimic classical drugs may offer new treatments, but their safety and efficacy require rigorous testing.